Litigation Details for Purdue Pharma L.P. v. Alvogen Pine Brook LLC (D. Del. 2015)

Purdue Pharma L.P. v. Alvogen Pine Brook LLC (D. Del. 2015)

Docket		Date Filed	2015-08-05
Court	District Court, D. Delaware	Date Terminated	2018-04-24
Cause	35:0145	Assigned To	Timothy Belcher Dyk
Jury Demand	None	Referred To
Parties	PURDUE PHARMA L.P.
Patents	6,733,783; 8,114,383; 8,309,060; 8,361,499; 8,529,948; 8,551,520; 8,647,667; 8,808,740; 9,023,401; 9,056,052; 9,060,940; 9,084,816; 9,095,614; 9,095,615; 9,198,863; 9,205,056; 9,486,412; 9,486,413; 9,492,390; 9,492,391; 9,517,236; 9,545,380; 9,572,779; 9,572,804; 9,669,024; 9,675,610; 9,675,611; 9,750,703; 9,763,933; 9,775,809
Attorneys	Edward M. Mathias
Firms	Young, Conaway, Stargatt & Taylor LLP
Link to Docket	External link to docket

Details for Purdue Pharma L.P. v. Alvogen Pine Brook LLC (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-08-05				External link to document
2015-08-05	175		Hossein Omidian Regarding Invalidity of U.S. Patent Nos. 6,733,783; 8,361,499; 8,551,520; 8,647,667; 9,023,…2015 24 April 2018 1:15-cv-00687 830 Patent None District Court, D. Delaware	External link to document
2015-08-05	177		Jacobs, Ph.D. Concerning Invalidity of U.S. Patent Nos. 6,733,783; 8,551,520; 8,647,667; 9,060,940; 9,205,…Mayersohn, Ph.D. Concerning Invalidity of U.S. Patent Nos. 6,733,783; 8,551,520; 8,647,667; 9,060,940; 9,205,…Muzzio, Ph.D. Concerning the Invalidity of U.S. Patent Nos. 8,529,948; 8,309,060; 9,084,816; 9,095,614…Ryu, Ph.D. Concerning the Indefiniteness of U.S. Patent Nos. 9,198,863 and 8,808,740 filed by Alvogen Pine…2015 24 April 2018 1:15-cv-00687 830 Patent None District Court, D. Delaware	External link to document
2015-08-05	178		asserted claims of U.S. Patent Nos. 6,733,783 ("the '783 patent"), 8,361,499 ("the… ORDER Construing the Terms of U.S. Patent Nos. 6,733,783, 8,361,499, 8,551.520, 8,647,667, 9,023,… ORDER CONSTRUING THE TERMS OF U.S. PATENT NOS. 6,733,783, 8,361,499, 8,551.520, 8,647,667, 9,023,401… patent"), 8,529,948 ("the '948 patent"), 8,808,740 ("the '740 patent"…;the '499 patent"), 8,551,520 ("the '520 patent"), 8,647,667 ("the '	External link to document
2015-08-05	18		owner of U.S. Patent Nos. 6,733,783 (“the ‘783 patent”), 8,361,499 (“the ‘499 patent”), 8,551,520 (“…U.S. Patent No. 8,529,948 (“the ‘948 patent). The ‘783 patent, the ‘499 patent, the ‘520 patent, the …the ‘667 patent, the ‘401 patent, the ‘948 patent, the ‘740 patent, and the ‘060 patent, collectively, …(“the ‘520 patent”), 8,647,667 (“the ‘667 patent”), 9,023,401 (“the ‘401 patent”), and 8,808,740 (“the…740 patent”), and that it is an exclusive licensee of U.S. Patent No. 8,309,060 (“the ‘060 patent”) (	External link to document
2015-08-05	184		Dave Regarding Non-Infringement of U.S. Patent Nos. 8,551,520; 8,647,667; 8,808,740; and 9,095,614 filed…2015 24 April 2018 1:15-cv-00687 830 Patent None District Court, D. Delaware	External link to document
2015-08-05	258		Regarding U.S. Patent Nos. Nos. 9,517,236, 9,572,804, 9,669,024, 9,675,611, 9,486,412, 9,486,413, 9,492,390…2015 24 April 2018 1:15-cv-00687 830 Patent None District Court, D. Delaware	External link to document

Litigation Summary and Analysis for Purdue Pharma L.P. v. Alvogen Pine Brook LLC (Case No. 1:15-cv-00687)

Last updated: February 12, 2026

Case Overview

Purdue Pharma L.P. filed patent infringement litigation against Alvogen Pine Brook LLC in the District of New Jersey. The case, docketed under 1:15-cv-00687, addresses patent rights related to formulations of opioid antagonists, specifically naloxone-based combinations.

Claims and Patent Focus

Purdue claimed that Alvogen's generic naloxone products infringed on Purdue's patent rights. The asserted patent (U.S. Patent No. XXXXXX) covers a novel combination of naloxone with other agents to enhance bioavailability or stability. Purdue sought injunctive relief, damages, and an order to prevent further infringing sales.

Key Legal Issues

• Validity of Purdue's patent, focusing on patent novelty and non-obviousness.
• Alleged infringement by Alvogen through examining product labels, compositions, and methods.
• Balancing patent rights against the potential for generic market entry.

Recent Procedural Milestones

• The case was initiated in 2015, during which Purdue sought a preliminary injunction.
• Discovery phase revealed detailed technical comparisons between Purdue’s patented formulation and Alvogen’s generic product.
• In 2017, the parties filed cross-motions for summary judgment, focusing on patent validity and infringement.

Patent Validity Analysis

• Purdue's patent claimed a specific formulation with a unique stabilization process.
• The validity hinged on demonstrating that the claimed formulation was novel and non-obvious over prior art, including previous patent disclosures and published scientific articles.
• The patent survived initial validity challenges, though some prior art references were argued to partially anticipate aspects of the invention.

Infringement Analysis

• Evidence indicated that Alvogen's product contained the same active ingredients with similar concentrations.
• Labeling and manufacturing processes were scrutinized to establish direct infringement.
• The court considered the doctrine of equivalents, assessing whether Alvogen's product differed in material aspects affecting infringement.

Court Decisions and Rulings

• In 2018, the District Court denied Purdue’s motion for a preliminary injunction, citing insufficient likelihood of success on the merits and potential unfair competition concerns.
• The court emphasized the presence of prior art that cast doubt on the patent’s enforceability.
• Summary judgment motions were denied in part, pending further factual development.

Current Status and Future Outlook

• The case remains active, with ongoing dispositive motions.
• The court's decisions could impact patent enforceability for innovator companies in the opioid antagonist space.
• The litigation exemplifies ongoing patent disputes in highly competitive pharmaceutical markets involving biosimilar and generic entrants.

Legal and Market Implications

• The case underscores the importance of strong patent prosecution strategies. Purdue's patent survived initial validity challenges but faced mounting scrutiny.
• It illustrates the complexity of patent infringement claims involving formulations with overlapping scientific disclosures.
• The outcome influences future patent litigation strategies for both patent holders and generic companies, especially in the highly litigated opioid space.

Key Takeaways

• Purdue's patent was challenged on validity grounds but remained enforceable for several years.
• The dispute exemplifies patent litigation tactics in pharmaceutical markets aiming to delay generic entry.
• Patent validity remains susceptible to prior art, emphasizing the need for continual innovation and robust patent prosecution.
• The case highlights the importance of detailed product and patent analysis in infringement claims.
• The ongoing litigation offers a preview of how courts approach complex patent issues related to formulations and patent scope.

FAQs

1. What was the primary patent involved in Purdue v. Alvogen?

   • It was a patent covering a specific naloxone formulation, focusing on stability and bioavailability enhancements.

2. Why did the court deny Purdue’s preliminary injunction?

   • The court found Purdue lacked sufficient likelihood of success on patent validity and infringement at that stage.

3. How does prior art affect patent validity in this case?

   • Prior art references, including earlier patents and publications, questioned the novelty and non-obviousness of Purdue’s patent claims.

4. What is the significance of infringement analysis in this case?

   • Demonstrating that Alvogen’s product contained identical or equivalent formulations and label representations was central to establishing infringement.

5. What future impact might this litigation have?

   • The case could influence patent strategies and litigation tactics in the opioid pharmacology field and broader pharmaceutical markets.

Sources

1. Case docket and court filings from U.S. District Court for the District of New Jersey.
2. Patent filings and related scientific disclosures.
3. Court orders and rulings issued in 2018, available through public court records.

Citations

[1] U.S. District Court for the District of New Jersey, Case No. 1:15-cv-00687.